SF3B1


Also found in: Dictionary.

SF3B1

A gene on chromosome 2q33.1 that encodes subunit 1 of the splicing factor SF3B, which is required for “A” complex assembly by the stable binding of U2 snRNP to the branchpoint sequence in pre-mRNA. Binding of the SF3A/SF3B complex upstream of the branch site may anchor U2 snRNP to pre-mRNA. SF3B1 may be involved in assembling the “E” complex.
Mentioned in ?
References in periodicals archive ?
Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.
Moreover, these newly discovered novel gene mutations, such as NOTCH1 , SF3B1 , and BIRC3,[sup][23] have been reported to be associated with disease progression and may have critical role in predicting the TTFT,[sup][23],[31] but they are not routinely evaluated in our clinical laboratory and were therefore not included in the development of this prognostic index.
With progress in understanding the molecular landscape of the tumor and the development of treatments targeting the pathways involving GNAQ/GNA11, BAP1, EIF1AX, SF3B1 mutations and epigenetic mechanisms, in the near future it may be possible to prevent the progression of micrometastases.
91) Among gene alterations found in MDS, mutations of the genes involved in DNA methylation and mRNA splicing--including TET2, IDH2, DNMT3a, SF3B1, and U2AF1--are thought to be present in the early phase of the disease.
The SF3B1 biomarker is included in our GeneReadTM DNAseq Leukemia V2 gene panel for next-generation sequencing," said Vincent Fert, QIAGEN s Personalized Healthcare Program Leader.
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Patients with mutations in the SF3B1 gene frequently had a specific abnormality of red blood cells in their bone marrow, called ring sideroblasts, researchers said.
Mutations of SF3B1 gene, which is a key component of the spliceosome machinery and will be targeted by a novel test, show a more favourable disease progression for patients than the "wild-type" gene, hence testing for these gene variants could provide crucial guidance for personalised treatment to MDS.
Some of the mutated genes that have been identified in pancreatic cancer and have been added to clinical testing panels include MLL3, TGFBR2, ARID1A, SF3B1, ATM, and ARID2.
The company's MDS testing covers all known molecular mutations associated with the disease, providing analysis of the following genes, either as a group, or individually - SF3B1, U2AF1, SRSF2, ZRSR2, RUNX1, EZH2, ASXL1, TET2, TP53, NRAS, CBL, PTPN11, IDH1/2 and ETV6.
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.
Four of the most commonly mutated splicing factors are SF3B1 (splicing factor 3b subunit 1), SRSF2 (serine/arginine rich splicing factor 2), ZRSR2 (zinc finger RNA-binding motif and serine/arginine rich 2), and U2AF1 (U2 small nuclear RNA auxiliary factor 1, also known as U2AF35).